A multijurisdictional Life Sciences team advised Gubra A/S ("Gubra") on its licensing agreement with AbbVie Inc. to develop a potential best-in-class, long-acting amylin analog for the treatment of obesity. Under this arrangement, believed to be the largest to date in Europe for a Phase 1 asset, Gubra will receive $350 million in total upfront payments and will be eligible to receive up to $1.875 billion in development, commercial and sales milestone payments, in addition to tiered royalties on global net sales. The transaction is subject to regulatory approvals and other customary closing conditions.
GUB014295 is currently in a Phase 1 clinical trial for the treatment of obesity, and under the license agreement AbbVie will obtain global rights to develop and commercialize GUB014295. This partnership marks AbbVie’s entrance into the obesity field.
Gubra is a company listed on Nasdaq Copenhagen specializing in preclinical research services and peptide-based drug discovery within metabolic and fibrotic diseases.
Goodwin is proud to have advised Gubra on this strategically important transaction.
The firm’s core deal team was led by Morag Peberdy, Adam Bellack, Kristopher Brown and Lucy Charlton, with assistance from Arman Oruc on antitrust and competition law issues.
For more information on the deal, please read the press release and coverage in FIERCE Biotech, Pharmaceutical Technology and Bloomberg.